Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Ozatilgan A"'
Autor:
de Wit, R., Wülfing, C., Castellano, D., Kramer, G., Eymard, J.-C., Sternberg, C.N., Fizazi, K., Tombal, B., Bamias, A., Carles, J., Iacovelli, R., Melichar, B., Sverrisdóttir, Á., Theodore, C., Feyerabend, S., Helissey, C., Foster, M.C., Ozatilgan, A., Geffriaud-Ricouard, C., de Bono, J.
Publikováno v:
In ESMO Open October 2021 6(5)
Autor:
Sternberg, Cora N., Castellano, Daniel, de Bono, Johann, Fizazi, Karim, Tombal, Bertrand, Wülfing, Christian, Kramer, Gero, Eymard, Jean-Christophe, Bamias, Aristotelis, Carles, Joan, Iacovelli, Roberto, Melichar, Bohuslav, Sverrisdóttir, Ásgerður, Theodore, Christine, Feyerabend, Susan, Helissey, Carole, Poole, Elizabeth M., Ozatilgan, Ayse, Geffriaud-Ricouard, Christine, de Wit, Ronald
Publikováno v:
In European Urology October 2021 80(4):497-506
Autor:
Sumanasuriya, Semini, Seed, George, Parr, Harry, Christova, Rossitza, Pope, Lorna, Bertan, Claudia, Bianchini, Diletta, Rescigno, Pasquale, Figueiredo, Ines, Goodall, Jane, Fowler, Gemma, Flohr, Penelope, Mehra, Niven, Neeb, Antje, Rekowski, Jan, Eisenberger, Mario, Sartor, Oliver, Oudard, Stéphane, Geffriaud-Ricouard, Christine, Ozatilgan, Ayse, Chadjaa, Mustapha, Macé, Sandrine, Lord, Chris, Baxter, Joe, Pettitt, Stephen, Lambros, Maryou, Sharp, Adam, Mateo, Joaquin, Carreira, Suzanne, Yuan, Wei, de Bono, Johann S. ⁎
Publikováno v:
In European Urology August 2021 80(2):243-253
Autor:
Thiery-Vuillemin, A., Fizazi, K., Sartor, O., Oudard, S., Bury, D., Thangavelu, K., Ozatilgan, A., Poole, E.M., Eisenberger, M., de Bono, J.
Publikováno v:
In ESMO Open April 2021 6(2)
Autor:
Alexander Meisel, Ronald de Wit, Stephane Oudard, Oliver Sartor, Frank Stenner-Liewen, Zhenming Shun, Meredith Foster, Ayse Ozatilgan, Mario Eisenberger, Johann S. de Bono
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background and purpose: Chemotherapy-induced neutropenia and neutrophil-to-lymphocyte ratio (NLR) are potentially useful prognostic markers in patients with metastatic castration-resistant prostate cancer (mCRPC). This post hoc analysis investigated
Externí odkaz:
https://doaj.org/article/64e2736141b249ca9f83a58bb38e988a
Autor:
Fizazi, Karim *, Kramer, Gero, Eymard, Jean-Christophe, Sternberg, Cora N, de Bono, Johann, Castellano, Daniel, Tombal, Bertrand, Wülfing, Christian, Liontos, Michael, Carles, Joan, Iacovelli, Roberto, Melichar, Bohuslav, Sverrisdóttir, Ásgerður, Theodore, Christine, Feyerabend, Susan, Helissey, Carole, Oudard, Stéphane, Facchini, Gaetano, Poole, Elizabeth M, Ozatilgan, Ayse, Geffriaud-Ricouard, Christine, Bensfia, Samira, de Wit, Ronald
Publikováno v:
In The Lancet Oncology November 2020 21(11):1513-1525
Autor:
Ronald de Wit, Stephen J. Freedland, Stephane Oudard, Georgi Marinov, Philippe Capart, Austin J. Combest, Ryan Peterson, Ayse Ozatilgan, Alicia K. Morgans
Publikováno v:
Prostate Cancer and Prostatic Diseases, 26(1), 67-73. Nature Publishing Group
Background The CARD study demonstrated superiority of cabazitaxel over abiraterone/enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who received prior docetaxel and progressed ≤12 months on the alternative andro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19908dea9abcf7df2635f3a839212aad
https://doi.org/10.1038/s41391-021-00487-1
https://doi.org/10.1038/s41391-021-00487-1
Autor:
Johann S. de Bono, Carole Helissey, Roberto Iacovelli, Bohuslav Melichar, Gero Kramer, Elizabeth M. Poole, Joan Carles, Christine Theodore, Aristotelis Bamias, Christian Wülfing, Ronald de Wit, Karim Fizazi, Jean-Christophe Eymard, Daniel Castellano, Ásgerður Sverrisdóttir, Susan Feyerabend, Christine Geffriaud-Ricouard, Ayse Ozatilgan, Bertrand Tombal, Cora N. Sternberg
Publikováno v:
European Urology, 80(4), 497-506. Elsevier
European Urology, Vol. 80, no. 4, p. 497-506 (2021)
European Urology, Vol. 80, no. 4, p. 497-506 (2021)
Background: In the CARD study (NCT02485691), cabazitaxel significantly improved median radiographic progression-free survival (rPFS) and overall survival (OS) versus abiraterone/enzalutamide in patients with metastatic castration-resistant prostate c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::855ca63ac5d77345d67181e5d8bdb3a5
https://doi.org/10.1016/j.eururo.2021.06.021
https://doi.org/10.1016/j.eururo.2021.06.021
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ronald de Wit, Gero Kramer, Carole Helissey, Roberto Iacovelli, Daniel Castellano, Susan Feyerabend, Stéphane Oudard, Bohuslav Melichar, Gaetano Facchini, Ayse Ozatilgan, Christian Wülfing, Christine Theodore, Ásgerður Sverrisdóttir, Johann S. de Bono, Christine Geffriaud-Ricouard, Bertrand Tombal, Samira Bensfia, Cora N. Sternberg, Karim Fizazi, M. Liontos, Jean-Christophe Eymard, Elizabeth M. Poole, Joan Carles
Publikováno v:
Lancet Oncology, 21(11), 1513-1525. Lancet Publishing Group
Lancet Oncology
Lancet Oncology, Elsevier, 2020, 21, pp.1513-1525. ⟨10.1016/S1470-2045(20)30449-6⟩
The Lancet Oncology, Vol. 21, no. 11, p. 1513-1525 (2020)
Lancet Oncology
Lancet Oncology, Elsevier, 2020, 21, pp.1513-1525. ⟨10.1016/S1470-2045(20)30449-6⟩
The Lancet Oncology, Vol. 21, no. 11, p. 1513-1525 (2020)
BACKGROUND: In the CARD study, cabazitaxel significantly improved radiographic progression-free survival and overall survival versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1bd2b066feb2208404b38f183755ac8
https://pure.eur.nl/en/publications/5fe2d06f-9d36-455e-ab42-4e790199991e
https://pure.eur.nl/en/publications/5fe2d06f-9d36-455e-ab42-4e790199991e